Proxy Statement on the Following Pages Describe the Formal Business to Be Transacted at the Annual Meeting
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-Of-Its-Kind Global Life Sciences Real Estate Platform
FROM: TISHMAN SPEYER Rubenstein Communications, Inc. – Public Relations Contact: Steven Rubenstein (212) 843-8043 Rick Matthews (212) 843-8267 BELLCO CAPITAL Contact: Leah Couvelier (213) 304-9333 Tishman Speyer and Bellco Capital Launch Breakthrough Properties, a First-of-Its-Kind Global Life Sciences Real Estate Platform Unique Collaboration Combines First-Hand Biotechnology Entrepreneurship and Scientific Research Experience with Unsurpassed Commercial Real Estate Development Capabilities Newly-Formed Joint Venture Acquires its First Development Site, in Boston’s Seaport District New York/Los Angeles/Boston – July 16, 2019 - Tishman Speyer, one of the world’s leading developers, owners, operators and asset managers of first-class real estate, and Bellco Capital (“Bellco”), an investment firm founded by biotechnology entrepreneurs Drs. Rebecka and Arie Belldegrun, have formed Breakthrough Properties (“Breakthrough”). The new company will acquire, develop and operate life science properties in leading technology centers around the world to support scientific innovation across biotechnology, agriculture and nutrition. Board Co-Chairs for Breakthrough are Bellco’s Arie Belldegrun and Tishman Speyer President & CEO Rob Speyer. Dan Belldegrun, a long-term member of Tishman Speyer’s Acquisitions and Development team, has been appointed Chief Executive Officer. The partners also announced today that Breakthrough has acquired its first property, taking advantage of Tishman Speyer’s deep roots and expertise as a commercial real estate developer and operator in the Boston market. The development site is strategically located by the Red Line on a one-acre parcel along the A Street corridor in Boston’s Seaport District and comes with 250,000 square feet of development rights. Completion of the project is anticipated in 2021. -
A Look at How Five of the Biggest Tech Companies Probe New Terrain
THEMIDDLEMARKET.COM MARCH 2020 A look at how fi ve of the biggest tech companies probe new terrain through early-stage investments CV1_MAJ0320.indd 1 2/24/20 4:16 PM Gain way. We designed our M&A Escrow experience to be a straight line from start to finish. With our comprehensive Deal Dashboard, streamlined KYC and account opening, and high-touch service through a single point of contact, try a better way on your next deal. Learn more at srsacquiom.com 0C2_MAJ0320 2 2/24/2020 11:54:58 AM Contents March 2020 | VOL. 55 | NO. 3 Cover Story 16 Fresh Terrain A look at how five of the biggest tech companies explore new territory through early-stage investments. Features 24 Viral impact How the coronavirus is affecting M&A and private equity. 27 Top investment banks Houlihan Lokey leads list based on volume of PE-backed U.S. deals 30 Top private equity firms Audax ranks first in U.S. deals. Private Equity Perspective 14 Record year for fundraising Blackstone’s $26 billion fund marked the largest buyout fund ever raised. The Buyside 15 Taking a new path XPO Logistics is selling assets and has Watercooler hired a new CFO to lead the process. 6 10 Guest article Climate change draws PE Future of auto 33 KKR raises first global impact fund to BorgWarner acquires Delphi to Women on board target clean water. position for auto industry shift. Gender diversity on corporate boards is good for performance and for 8 12 shareholders. Protecting businesses Why investors like steaks Advent and Crosspoint buy Smith & Wollensky owner purchases cybersecurity firm Forescout. -
ALLOGENE THERAPEUTICS, INC. (Name of Registrant As Specified in Its Charter)
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to § 240.14a-12 ALLOGENE THERAPEUTICS, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement if other than the Registrant) Payment of Filing Fee (Check the appropriate box) ☒ No fee required. ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. Title of each class of securities to which transaction applies: Aggregate number of securities to which transaction applies: Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): Proposed maximum aggregate value of transaction: Total fee paid: ☐ Fee paid previously with preliminary materials. ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. Amount previously paid: Form, Schedule or Registration Statement No.: Filing party: Date Filed: ALLOGENE THERAPEUTICS, INC. 210 East Grand Avenue South San Francisco, California 94080 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On June 6, 2019 Dear Stockholder: You are cordially invited to attend the 2019 Annual Meeting of Stockholders of Allogene Therapeutics, Inc., a Delaware corporation (the “Company”). -
Community Partners Bancorp
COMMUNITY PARTNERS BANCORP FORM 10-K (Annual Report) Filed 03/31/08 for the Period Ending 12/31/07 Address 1250 HIGHWAY 35 SOUTH MIDDLETOWN, NJ 07748 Telephone 732-706-9009 CIK 0001343034 Symbol CPBC SIC Code 6022 - State Commercial Banks Industry Regional Banks Sector Technology Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2008, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2007 TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to _______ Commission file Number: 000 -51889 COMMUNITY PARTNERS BANCORP (Exact Name of Registrant as Specified in Its Charter) New Jersey 20 -3700861 (State or Other Jurisdiction of IRS Employer Identification Number) Incorporation or Organization) 1250 Highway 35 South, Middletown, NJ 07748 (Address of Principal Executive Offices, including Zip Code) (732) 706 -9009 (Registrant ’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Common Stock, no par value (Title of Class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. -